CD73: A potential biomarker for anti-PD-1 therapy

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A(2A) blockade. Since CD73 is known to be overexpressed in several human cancers and A(2A) antagonists have undergone clinical trials for Parkinson's Disease, t...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncoimmunology
Egile Nagusiak: Beavis, Paul A, Slaney, Clare Y, Milenkovski, Nicole, Henderson, Melissa A, Loi, Sherene, Stagg, John, Kershaw, Michael H, Darcy, Phillip K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2015
Gaiak:
Author's View
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4589050/
https://ncbi.nlm.nih.gov/pubmed/26451321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1046675
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak